TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. ("Vaxil" or the "Company") (TSX VENTURE: VXL), is pleased to announce that the Company completed its previously announced non-brokered private placement (see press release dated November 24, 2025) for gross proceeds of $140,000 (the "Private Placement"). Investors in the Private Placement subscribed for 1,244,441 units ("Units") at a price of $0.1125 per Unit. Each Unit consisted of one common share in the capital of the Company ("Common Share") and one Common Share purchase warrant ("Warrant"), with each Warrant being exercisable, at any time prior to December 2, 2030, to acquire one additional Common Share (each a "Warrant Share") at an exercise price of $0.15 per Warrant Share.